专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

51. 发明授权

US5968989A Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor 失效
公开(公告)号：US5968989A
公开(公告)日：1999-10-19
申请号：US472817
申请日：1995-06-07
申请人： Ronald M. Evans , David J. Mangelsdorf , Richard A. Heyman , Marcus F. Boehm , Gregor Eichele , Christina Thaller
发明人： Ronald M. Evans , David J. Mangelsdorf , Richard A. Heyman , Marcus F. Boehm , Gregor Eichele , Christina Thaller
IPC分类号： A61K31/07 , A61K31/19 , A61K31/20 , A61K31/203 , A61K31/23 , A61K31/232 , A61K38/21 , C07C53/00 , C07C57/26 , C07C59/46 , C07C59/80 , C07K14/705 , C12P7/04 , A01N31/04 , A01N37/00
CPC分类号： C07K14/70567 , A61K31/07 , A61K31/19 , A61K31/20 , A61K31/203 , A61K31/23 , A61K31/232 , C07C403/20 , C07C57/26 , C07C59/46 , C07C59/80 , C12P7/04 , C07B2200/09 , C07C2101/16
摘要： In accordance with the present invention, there are provided methods to modulate processes mediated by retinoid receptors, employing high affinity, high specificity ligands for such receptors. In one aspect of the present invention, there are provided ligands which are more selective for the retinoid X receptor than is retinoic acid (i.e., rexoids). In another aspect of the present invention, alternative ligands (other than retinoic acid) have been discovered which are capable of inducing retinoic acid receptor mediated processes. In yet another aspect, methods have been developed for the preparation of such retinoid receptor ligands from readily available compounds.

52. 发明授权

US5932622A Method for in vivo modulation of non-malignant skin-related processes with 9-cis-retinoic acid 失效
标题翻译：用9-顺 - 视黄酸体内调节非恶性皮肤相关过程的方法
公开(公告)号：US5932622A
公开(公告)日：1999-08-03
申请号：US475174
申请日：1995-06-07
申请人： Ronald M. Evans , David J. Mangelsdorf , Richard A. Heyman , Marcus F. Boehm , Gregor Eichele , Christina Thaller
发明人： Ronald M. Evans , David J. Mangelsdorf , Richard A. Heyman , Marcus F. Boehm , Gregor Eichele , Christina Thaller
IPC分类号： A61K31/203 , A61K31/232 , A61K31/07 , C12N5/06
CPC分类号： A61K31/203 , A61K31/232 , Y10S514/863 , Y10S514/864
摘要： A method for modulating non-malignant skin related disorders in a subject has been demonstrated with 9-cis retinoic acid. Wrinkling, acne, keratinization, differentiation and proliferation disorders are treated by administration of 9-cis retinoic acid alone or in a pharmaceutically acceptable carrier to a subject in need thereof.
摘要翻译：用9-顺式视黄酸证明了调节受试者中非恶性皮肤相关疾病的方法。通过将9-顺式视黄酸单独或药学上可接受的载体给予有需要的受试者来治疗皱纹，粉刺，角质化，分化和增殖障碍。

53. 发明授权

US5747661A Retinoid-inducible response elements 失效
标题翻译：类视黄醇诱导型应答元件
公开(公告)号：US5747661A
公开(公告)日：1998-05-05
申请号：US373935
申请日：1995-01-13
申请人： Ronald M. Evans , David J. Mangelsdorf , Patricia J. Willy
发明人： Ronald M. Evans , David J. Mangelsdorf , Patricia J. Willy
IPC分类号： A61K38/00 , C07K14/705 , C12N15/85
CPC分类号： C07K14/70567 , A61K38/00
摘要： The characterization of LXR.alpha., an orphan member of the nuclear hormone receptor superfamily that can function as a tissue-specific mediator of 9-cis retinoic acid (9cRA) is described herein. When expressed in cells, LXR.alpha. activates transcription in response to 9cRA on a distinct response element, termed an LXRE. Significantly, neither RXR homodimers nor RXR/RAR heterodimers are able to substitute for LXR.alpha. in mediating this retinoid response. The LXR.alpha. response to retinoids is due to its unique interaction with endogenous RXR. This interaction shifts RXR from its previously described role as a silent, heterodimer partner to an active ligand binding partner, thus defining a novel retinoid response pathway.
摘要翻译：本文描述了可用作9-顺式视黄酸（9cRA）的组织特异性介质的核激素受体超家族的孤儿成员的LXRα的表征。当在细胞中表达时，LXRα响应于9cRA在不同的响应元件（称为LXRE）上激活转录。值得注意的是，RXR同源二聚体和RXR / RAR异源二聚体都不能在介导这种类视黄醇反应中替代LXRα。对类维生素A的LXRα反应是由于其与内源性RXR的独特相互作用。这种相互作用将RXR从其先前描述的作为静默的异二聚体配偶体的作用转移到活性配体结合配偶体，从而定义了新的维甲酸反应途径。

54. 发明授权

US5702914A Use of reporter genes for retinoid receptor screening assays having novel retinoid-associated response elements 失效
标题翻译：报道基因用于具有新颖类视黄醇相关反应元件的维甲酸受体筛选试验
公开(公告)号：US5702914A
公开(公告)日：1997-12-30
申请号：US360939
申请日：1994-12-21
申请人： Ronald M. Evans , Toshihiko Ogura
发明人： Ronald M. Evans , Toshihiko Ogura
IPC分类号： C07K14/47 , C07K14/705 , C12N15/12 , C12N15/67 , C12Q1/02
CPC分类号： C07K14/70567 , C07K14/47 , C07K2319/00
摘要： In accordance with the present invention, there are provided novel cotranscription factors that function to enhance mRNA transcription in cooperation with retinoid receptors. Also provided are novel DNA response elements, DNA constructs and expression vectors containing said constructs useful for providing cell-specific gene expression. Bioassays are also provided that are useful for evaluating whether a compound is a functional ligand (e.g., agonist or antagonist) for retinoid receptor protein(s), or functional engineered or modified forms thereof.
摘要翻译：根据本发明，提供了与类视黄醇受体合作增强mRNA转录的新型共转录因子。还提供了新颖的DNA应答元件，DNA构建体和含有用于提供细胞特异性基因表达的所述构建体的表达载体。还提供了可用于评估化合物是否为类视黄醇受体蛋白质的功能性配体（例如激动剂或拮抗剂）或其功能性工程化或修饰形式的生物测定。

55. 发明授权

US5668175A Use of selective ligands for treatment of disease states responsive to steroid or steroid-like retinoids 失效
标题翻译：使用选择性配体治疗对类固醇或类固醇样类视色素有反应的疾病状态
公开(公告)号：US5668175A
公开(公告)日：1997-09-16
申请号：US695743
申请日：1996-08-12
申请人： Ronald M. Evans , Richard A. Heyman , Christina S. Berger , Robert B. Stein
发明人： Ronald M. Evans , Richard A. Heyman , Christina S. Berger , Robert B. Stein
IPC分类号： A61K31/00 , A61K31/192 , A61K31/196 , A61K31/203 , A61K31/19 , A61K31/165
CPC分类号： A61K31/203 , A61K31/00 , A61K31/192 , A61K31/196
摘要： In accordance with the present invention, there is provided a method for the treatment of subjects afflicted with steroid or steroid-like hormone-responsive disease states. The invention method comprises administering to the subject an effective amount of a ligand which selectively interacts with the receptor subtype associated with the steroid or steroid-like hormone-responsive disease state, wherein said ligand interacts with said receptor subtype to a significantly greater extent than with other subtypes of the same receptor class.
摘要翻译：根据本发明，提供了治疗患有类固醇或类固醇激素反应性疾病状态的受试者的方法。本发明方法包括向受试者施用有效量的与类固醇或类固醇样激素反应性疾病状态相关的受体亚型选择性相互作用的配体，其中所述配体与所述受体亚型相互作用明显大于与同一受体类别的其他亚型。

56. 发明授权

US5597693A Hormone response element compositions and assay 失效
标题翻译：激素反应元件组成和测定
公开(公告)号：US5597693A
公开(公告)日：1997-01-28
申请号：US494618
申请日：1990-03-16
申请人： Ronald M. Evans , Kazuhiko Umesono
发明人： Ronald M. Evans , Kazuhiko Umesono
IPC分类号： C07K7/06 , C07K14/00 , C07K14/435 , C07K14/705 , C07K14/72 , C12N15/09 , C12P21/02 , C12Q1/68 , C12R1/91
CPC分类号： C12Q1/6897 , C07K14/721
摘要： The present invention discloses steroid/thyroid hormone receptor DNA binding domain compositions that determine target gene specificity. The invention further discloses methods converting the target gene specificity of one receptor into the target gene specificity of another. Still further the invention discloses novel assays for identifying ligands for orphan hormone receptors. These assays are especially useful since they avoid the necessity of constructing chimeric genes and proteins in order to search for ligands that can activate a putative receptor.
摘要翻译：本发明公开了确定靶基因特异性的类固醇/甲状腺激素受体DNA结合结构域组合物。本发明还公开了将一种受体的靶基因特异性转化为另一种受体的靶基因特异性的方法。本发明进一步公开了用于鉴定孤儿激素受体配体的新型测定法。这些测定是特别有用的，因为它们避免了构建嵌合基因和蛋白质的需要，以便搜索可以激活推定受体的配体。

57. 发明授权

US5260432A Human gamma retinoic acid receptor DNA 失效
标题翻译：人类视网膜酸受体DNA
公开(公告)号：US5260432A
公开(公告)日：1993-11-09
申请号：US370407
申请日：1989-06-22
申请人： Fumimaro Takaku , Takashi Ishikawa , Michio Imawari , Ronald M. Evans , Kazuhiko Umesono
发明人： Fumimaro Takaku , Takashi Ishikawa , Michio Imawari , Ronald M. Evans , Kazuhiko Umesono
IPC分类号： A61K38/00 , C07K14/00 , C07K14/705 , C07K14/72 , C07K19/00 , C12N5/10 , C12N15/09 , C12P21/02 , C12R1/91 , C07H21/04 , C07H21/02 , C12Q1/68
CPC分类号： C07K14/72 , C07K14/70567 , C07K14/721 , A61K38/00 , C07K2319/00 , C07K2319/715 , C07K2319/80 , Y10S530/826 , Y10S530/846
摘要： A novel gamma retinoic acid receptor is disclosed. The novel receptor is encoded for by cDNA carried on plasmid pGEM-hRAR.gamma., which has been deposited with the American Type Culture Collection for patent purposes. Chimeric receptor proteins are also disclosed. The chimera contain at least one functional domain from the new gamma retinoic acid receptor.
摘要翻译：公开了一种新型的视黄酸受体。新型受体由携带在质粒pGEM-hRARγ上的cDNA编码，其已经保藏在美国典型培养物保藏中心用于专利。还公开了嵌合受体蛋白。嵌合体含有来自新的视黄酸受体的至少一个功能结构域。

58. 发明授权

US5217867A Receptors: their identification, characterization, preparation and use 失效
标题翻译：受体：他们的鉴定，表征，制备和使用
公开(公告)号：US5217867A
公开(公告)日：1993-06-08
申请号：US278614
申请日：1988-11-30
申请人： Ronald M. Evans , Stanley M. Hollenberg
发明人： Ronald M. Evans , Stanley M. Hollenberg
IPC分类号： C12N15/09 , C07H21/04 , C07K14/435 , C07K14/705 , C07K14/72 , C12N5/10 , C12N15/12 , C12N15/85 , C12P21/00 , C12Q1/48 , C12Q1/68 , C12R1/91 , G01N33/566 , G01N33/574 , G01N33/74
CPC分类号： G01N33/574 , C07K14/721 , C12N15/85 , C12Q1/6897 , G01N33/566 , G01N33/743 , C07K2319/00 , C07K2319/61 , C07K2319/715 , C07K2319/81 , C12N2830/002 , C12N2830/15 , C12N2830/60 , G01N2333/723 , G01N2500/00
摘要： Disclosed are novel hormone and hormone-like receptors wherein the trans-activation transcription domain(s) is modified in terms of position and/or copy number or otherwise versus parent receptor, such novel receptors having increased trans-activation transcription activation properties surprisingly superior to the parent receptor. Also disclosed are the recombinant methods and means for preparing such receptors and assays based upon the use of such receptors for screening and identifying putative materials that can affect such receptors and/or for the expression via induced transcription of a reporter or other desired, preferably heterologous gene or DNA product.

59. 发明申请

US20120302491A1 MODULATION OF ESTROGEN RECEPTOR-RELATED RECEPTOR GAMMA (ERR GAMMA) AND USES THEREFOR 有权
标题翻译：雌激素受体相关受体GAMMA（ERR GAMMA）的调节及其用途
公开(公告)号：US20120302491A1
公开(公告)日：2012-11-29
申请号：US13410142
申请日：2012-03-01
申请人： Vihang A. Narkar , Michael Downes , Ruth T. Yu , Ronald M. Evans
发明人： Vihang A. Narkar , Michael Downes , Ruth T. Yu , Ronald M. Evans
IPC分类号： A61K38/02 , A61K31/16 , A61P13/12 , A61P9/00 , A61P25/00 , A61K48/00 , A61P21/00
CPC分类号： A61K38/1796 , A61K31/166 , A61K31/381 , A61K31/655 , A61K38/177 , A61K48/00 , A61K48/005 , A61K48/0058 , A61K48/0066
摘要： This application provides methods of increasing vascularization, muscle performance, muscle rehabilitation, and/or mitochondrial activity in subjects in need thereof, by administering a therapeutically effective amount of one or more agents that increases ERRγ activity to the subject. Such agents can include one or more ERRγ agonists. In some examples the method does not require that the subject exercise, and as such, the subject may be sedentary (such as bedridden or in a wheelchair).
摘要翻译：本申请提供了通过施用治疗有效量的一种或多种增加对受试者的ERRγ活性的药物来增加血管形成，肌肉功能，肌肉恢复和/或线粒体活性的方法。这样的试剂可以包括一种或多种ERRγ激动剂。在一些例子中，该方法不要求主体锻炼，因此主体可能是久坐的（如卧床不起或在轮椅上）。

60. 发明授权

US07972782B2 Steroid-activated nuclear receptors and uses therefor 有权
标题翻译：类固醇激活的核受体及其用途
公开(公告)号：US07972782B2
公开(公告)日：2011-07-05
申请号：US11495263
申请日：2006-07-27
申请人： Ronald M. Evans , Bruce Blumberg
发明人： Ronald M. Evans , Bruce Blumberg
IPC分类号： C12Q1/68
CPC分类号： A01K67/0275 , A01K2217/05 , A01K2227/105 , A01K2267/03 , A61K38/00 , C07K14/70567 , C07K2319/71 , C12N15/8509 , C12N2830/008 , C12Q1/6897 , G01N33/743 , G01N2333/90245 , G01N2500/00
摘要： A novel nuclear receptor, termed the steroid and xenobiotic receptor (SXR), a broad-specificity sensing receptor that is a novel branch of the nuclear receptor superfamily, has been discovered. SXR forms a heterodimer with RXR that can bind to and induce transcription from response elements present in steroid-inducible cytochrome P450 genes in response to hundreds of natural and synthetic compounds with biological activity, including therapeutic steroids as well as dietary steroids and lipids. Instead of hundreds of receptors, one for each inducing compound, the invention SXR receptors monitor aggregate levels of inducers to trigger production of metabolizing enzymes in a coordinated metabolic pathway. Agonists and antagonists of SXR are administered to subjects to achieve a variety of therapeutic goals dependent upon modulating metabolism of one or more endogenous steroids or xenobiotics to establish homeostasis. An assay is provided for identifying steroid drugs that are likely to cause drug interaction if administered to a subject in therapeutic amounts. Transgenic animals are also provided which express human SXR, thereby serving as useful models for human response to various agents which potentially impact P450-dependent metabolic processes.
摘要翻译：已经发现了一种称为类固醇和异种生物受体（SXR）的新型核受体，作为核受体超家族的新分支的广泛特异性感受器受体。 SXR与RXR形成异源二聚体，其可以结合并诱导存在于类固醇诱导细胞色素P450基因中的响应元件的转录，以响应数百种具有生物活性的天然和合成化合物，包括治疗类固醇以及膳食类固醇和脂质。代替数百个受体，每个诱导化合物一个，本发明SXR受体监测诱导剂的总体水平以引发协同代谢途径中代谢酶的产生。 SXR的激动剂和拮抗剂被施用于受试者以实现依赖于调节一种或多种内源性类固醇或异种生物的代谢以建立体内平衡的多种治疗目标。提供了用于鉴定如果以治疗量施用给受试者的可能引起药物相互作用的类固醇药物的测定。还提供了表达人SXR的转基因动物，从而作为人类对各种可能影响P450依赖性代谢过程的药物的反应的有用模型。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式